ERBB2 and neutropenia: Results from a meta-analysis indicated that S-1-based therapy showed significant ORR, longer PFS, and longer OS than S-1 monotherapy, although with higher incidence of grade 3 to 4 neutropenia.5 In a retrospective trail that compared S-1 plus cisplatin (SP) to capecitabine plus cisplatin (XP), SP and XP were associated with similar efficacy and safety in AGC patients.16 However, for elderly HER2-positive ACG patients, trastuzumab might be a better treatment option than S-1.